Immunotherapy in Non-Small Cell Lung Cancer: Answering Clinically Relevant Questions
Sunday, June 5, 2016
Sheraton Grand Chicago • Chicago, Illinois
Presented by prIME Oncology in collaboration with the Society for Immunotherapy of Cancer
This satellite symposium, which was held during the 2016 ASCO Annual Meeting, presented recent findings from clinical trials investigating immunotherapeutic agents in newly diagnosed non-small cell lung cancer (NSCLC). Attendees learned how to apply these findings to appropriately selected patients, monitor efficacy of immunotherapies, recognize adverse events and apply methods to mitigate toxicity. The symposium also discussed the rationale for, and research findings on, novel combinations that include immunotherapies and other agents.
Click here to learn more about this program!
Chair
Roy S. Herbst, MD, PhD – Yale Cancer Center
Session Speakers and Topics
6:00 – 6:30 p.m. |
Registration and Dinner Welcome and Introduction Roy S. Herbst, MD, PhD – Yale Cancer Center |
6:30 – 6:45 p.m. 6:45 – 8:25 p.m. |
Recent Progress in Immunotherapy for NSCLC Roy S. Herbst, MD, PhD – Yale Cancer Center Taking It to the Clinic: Questions and Considerations All Faculty |
|
Question #1: Selection of Therapy in Advanced NSCLC Ramaswamy Govindan, MD – Washington University School of Medicine Faculty Panel Discussion |
|
Question #2: Monitoring Response to Immunotherapy Treatment Francesco Grossi, MD – National Institute for Cancer Research Faculty Panel Discussion |
|
Question #3: Managing Immune-Related Adverse Events Leena Gandhi, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School Faculty Panel Discussion |
|
Question #4: Immunotherapy Beyond Progression Ramaswamy Govindan, MD – Washington University School of Medicine Faculty Panel Discussion |
|
Question #5: Combining Immunotherapies with Other Treatment Approaches Francesco Grossi, MD – National Institute for Cancer Research Faculty Panel Discussion |
8:25 – 8:30 p.m. |
Closing Remarks: prIME Points Roy S. Herbst, MD, PhD – Yale Cancer Center |
Continuing Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Other Information
This educational activity was supported by grants from Incyte and Merck and Co, Inc.
Not an official event of the 2016 ASCO Annual Meeting
Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation